A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This clinical trial will study brentuximab vedotin with CHP to find out if the drugs work for
people who have certain types of peripheral T-cell lymphoma (PTCL). It will also find out
what side effects occur when brentuximab vedotin and CHP are used together. A side effect is
anything the drugs do besides treating cancer. CHP is a type of chemotherapy that uses three
drugs (cyclophosphamide, doxorubicin, and prednisone). CHP is approved by the FDA to treat
certain types of PTCL.